148 related articles for article (PubMed ID: 37910437)
1. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens.
Wu K; Koethe J; Hulgan T; Brown T; Bares SH; Tassiopoulos K; Lake JE; Leonard M; Samuels DC; Erlandson K; Haas DW
Pharmacogenet Genomics; 2024 Feb; 34(2):25-32. PubMed ID: 37910437
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Leonard MA; Cindi Z; Bradford Y; Bourgi K; Koethe J; Turner M; Norwood J; Woodward B; Erdem H; Basham R; Baker P; Rebeiro PF; Sterling TR; Hulgan T; Daar ES; Gulick R; Riddler SA; Sinxadi P; Ritchie MD; Haas DW
Clin Infect Dis; 2021 Oct; 73(7):e2153-e2163. PubMed ID: 32829410
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
Griesel R; Maartens G; Chirehwa M; Sokhela S; Akpomiemie G; Moorhouse M; Venter F; Sinxadi P
Clin Infect Dis; 2021 Dec; 73(11):e3902-e3909. PubMed ID: 32960272
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy.
Erlandson KM; Wu K; Lake JE; Samuels DC; Bares SH; Tassiopoulos K; Koethe JR; Brown TT; Leonard M; Benson CA; Haas DW; Hulgan T;
AIDS; 2021 Mar; 35(3):439-445. PubMed ID: 33252493
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
[TBL] [Abstract][Full Text] [Related]
7. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
8. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Lake JE; Wu K; Bares SH; Debroy P; Godfrey C; Koethe JR; McComsey GA; Palella FJ; Tassiopoulos K; Erlandson KM
Clin Infect Dis; 2020 Dec; 71(9):e471-e477. PubMed ID: 32099991
[TBL] [Abstract][Full Text] [Related]
10. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
Mollan KR; Tierney C; Hellwege JN; Eron JJ; Hudgens MG; Gulick RM; Haubrich R; Sax PE; Campbell TB; Daar ES; Robertson KR; Ventura D; Ma Q; Edwards DRV; Haas DW;
J Infect Dis; 2017 Sep; 216(5):554-564. PubMed ID: 28931220
[TBL] [Abstract][Full Text] [Related]
11. Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
Haas DW; Acosta EP
Clin Infect Dis; 2021 May; 72(10):1820-1822. PubMed ID: 32667979
[TBL] [Abstract][Full Text] [Related]
12. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R; Nightingale S; Brey N; Albertyn CH; Kellermann TA; Taljaard JJ; Esterhuizen TM; Sinxadi PZ; Decloedt EH
Clin Infect Dis; 2022 Aug; 75(3):399-405. PubMed ID: 34882770
[TBL] [Abstract][Full Text] [Related]
15. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N; Scarsi KK; Baker P; Smeaton LM; Podany AT; Olefsky M; Woolley E; Barr E; Pham M; Mawlana S; Supparatpinyo K; Gatechompol S; Jalil EM; Gadama L; Badal-Faesen S; Van Schalkwyk M; Kayama C; Belaunzaran-Zamudio PF; Godfrey C; Cohn SE; Mngqibisa R; Haas DW;
Pharmacogenet Genomics; 2023 Aug; 33(6):126-135. PubMed ID: 37306344
[TBL] [Abstract][Full Text] [Related]
18. Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide.
Palella FJ; Hou Q; Li J; Mahnken J; Carlson KJ; Durham M; Ward D; Fuhrer J; Tedaldi E; Novak R; Buchacz K
J Acquir Immune Defic Syndr; 2023 Jan; 92(1):67-75. PubMed ID: 36150045
[TBL] [Abstract][Full Text] [Related]
19. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
20. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
